CPMP/EWP/QWP/1401/98 Rev 1
Guideline on the investigation of bioequivalence
Current edition
Revision 1 (since 1 August 2010); parts replaced by ICH M13A in 2025
Current edition
Revision 1 (since 1 August 2010); parts replaced by ICH M13A in 2025
About this standard
Sets requirements for the design, conduct and evaluation of bioequivalence studies for immediate-release forms with systemic action, including the conditions for waiving studies.
Since 25 January 2025 ICH M13A replaces the parts of this guideline on non-replicate study designs. Other topics, such as replicate designs for highly variable drugs and narrow therapeutic index drugs, still apply.
Recognition by market
Whether the market recognizes, harmonizes or adopts this standard, and which edition it accepts
- AustraliaAdopted with changes
- Edition accepted
- -
- National code
- CPMP/EWP/QWP/1401/98 Rev. 1/Corr
Adopted guidelines are generally not required by law but give sponsors guidance on meeting the legal requirements.. Adopted with annotations: Good Clinical Practice follows the TGA-annotated EU note, and a generic application generally includes a bioequivalence study against an Australian leading brand.
- SwitzerlandReferenced
- Edition accepted
- -
- National code
- -
Partial recognition. Appendix II for rapid release non-oral forms; ICH M13A applies to rapid release oral forms.
- Saudi ArabiaReferenced
- Edition accepted
- -
- National code
- -
The SFDA Guidelines for Bioequivalence are adapted from this EMA guideline, with Saudi additions such as the reference product rule and the subject numbers.
- SingaporeReferenced
- Edition accepted
- -
- National code
- -
HSA advises applicants to know the ASEAN bioequivalence guideline, which was adopted from this EMA guideline, and to refer to EMA CHMP or US FDA guidelines for the conduct and analysis of bioequivalence studies.
Testing requirements that cite it
Open the market page and its pathway pages for the full requirement, protocol and report content
European Union
- Bioequivalence studies for immediate-release oral generics (ICH M13A with the EMA guideline)Bioequivalence · Not stated
- Biowaivers: BCS-based waivers and waivers for additional strengthsBioequivalence · Not stated
- Conduct of bioequivalence studies: GCP, GMP of study products and bioanalysisBioequivalence · Not stated
- Highly variable and narrow therapeutic index drugs in bioequivalence studiesBioequivalence · Not stated
- Reference medicinal product and test product for generic bioequivalenceBioequivalence · Not stated
Australia
- Bioequivalence studies: adopted EU guideline, dissolution profiles and reportingBioequivalence · Not stated
- When biopharmaceutic data are required, by type of applicationBioequivalence · Not stated
Switzerland
- Bioequivalence and comparative bioavailability studies for known active substancesBioequivalence · Not stated
Saudi Arabia
- Bioequivalence studies for generic medicines: design, subjects and acceptance limitsBioequivalence · Not stated
Singapore
- Bioequivalence limits for narrow therapeutic index drugs and highly variable drugsBioequivalence · Not stated
- Bioequivalence studies for generic drugs: when required, design, subjects and acceptance limitsBioequivalence · Not stated
Related standards: JP guideline for bioequivalence studies of generic products, MHRA comparator product guidance, JP BE guideline, formulation changes (oral solid), NMPA Notice 2016 No. 61, Annex 3, FDA BE guidance for ANDAs (PK endpoints), NMPA Notice 2016 No. 61, Annex 1, HC comparative bioavailability conduct guidance, HC comparative bioavailability standards, HC foreign-sourced reference product guidance, HC proportional formulations policy, M9, M13A. See all standards.